dlbcl

Showing 1 - 25 of 49

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With

Completed
  • DLBCL
  • Old Age; Debility
    • Homburg, Saarland, Germany
      Saarland University Medical Center
    Nov 20, 2023

    Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

    Recruiting
    • Lymphoma
    • +2 more
    • Shanghai, Shanghai, China
    • +2 more
    May 9, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

    Recruiting
    • CLL
    • +9 more
    • TG-1801
    • Ublituximab
    • Fayetteville, Arkansas
    • +4 more
    Jan 20, 2023

    Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

    Recruiting
    • Non-Hodgkin Lymphoma
    • +4 more
    • Duarte, California
    • +23 more
    Dec 28, 2022

    Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

    Recruiting
    • NSCLC
    • +6 more
    • Oral MRT-2359
    • Scottsdale, Arizona
    • +7 more
    Dec 20, 2022

    Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Dec 12, 2022

    DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)

    Recruiting
    • DLBCL
    • Diffuse Large B-Cell Lymphoma
    • Zilovertamab vedotin
    • +4 more
    • Whittier, California
    • +21 more
    Nov 30, 2022

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL Trial in United States (KT-413)

    Recruiting
    • Non Hodgkin Lymphoma
    • +3 more
    • Washington, District of Columbia
    • +5 more
    Nov 29, 2022

    Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

    Recruiting
    • Mantle Cell Lymphoma
    • +9 more
    • L-Bcl-2 antisense oligonucleotide
    • Augusta, Georgia
    • +2 more
    Nov 18, 2022

    Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

    Active, not recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • AUTO3
    • Duarte, California
    • +10 more
    Oct 19, 2022

    Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

    Recruiting
    • Large B-cell Lymphoma
    • DLBCL
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Oct 3, 2022

    DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)

    Recruiting
    • DLBCL
    • Tafasitamab and Lenalidomide
    • Hangzhou, Zhejiang, China
      The First Afflicated Hospital, College of Medicine, Zhejiang Uni
    Sep 21, 2022

    Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

    Not yet recruiting
    • Mature B-Cell Neoplasm
    • +25 more
    • (no location specified)
    Sep 14, 2022

    AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)

    Terminated
    • AML Including AML de Novo and AML Secondary to MDS
    • DLBCL
    • Birabresib Dose 20 mg
    • (no location specified)
    Aug 23, 2022

    Advanced Solid Tumor, DLBCL Trial in United States (RNK05047)

    Recruiting
    • Advanced Solid Tumor
    • DLBCL
    • Atlanta, Georgia
    • +3 more
    Aug 23, 2022

    DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

    Not yet recruiting
    • DLBCL
    • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
    • Qingdao, Shandong, China
      the affiliated hospital of Qingdao University
    Aug 18, 2022

    NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

    Completed
    • NHL
    • +3 more
    • Los Angeles, California
    • +11 more
    Aug 11, 2022

    DLBCL Trial in China (Orelabrutinib and Gemox)

    Not yet recruiting
    • DLBCL
    • Orelabrutinib and Gemox
    • Chongqing, Chongqing, China
    • +7 more
    Jul 5, 2022

    DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

    Recruiting
    • DLBCL
    • +3 more
    • Minneapolis, Minnesota
      University of Minnesota, Masonic Cancer Center
    Jul 1, 2022

    DLBCL Trial in United States (MB-CART2019.1)

    Recruiting
    • DLBCL
    • MB-CART2019.1
    • Gilbert, Arizona
    • +14 more
    Jun 17, 2022

    Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

    Recruiting
    • DLBCL
    • +8 more
    • Cardiac MRI
    • Bonn, NRW, Germany
      University Hospital Bonn
    Jun 11, 2022

    Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

    Recruiting
    • Advanced Solid Tumor
    • +9 more
    • Phoenix, Arizona
    • +20 more
    May 2, 2022

    Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

    Not yet recruiting
    • Primary Extranodal Lymphoma
    • DLBCL
    • (no location specified)
    Apr 6, 2022

    CLL/SLL, NHL, MCL Trial in United States (HMPL-760)

    Recruiting
    • CLL/SLL
    • +8 more
    • Atlanta, Georgia
    • +3 more
    Feb 24, 2022